-DOCSTART- -X- O
Naturally -X- _ O
occurring -X- _ O
strains -X- _ O
of -X- _ O
Newcastle -X- _ B-Intervention
disease -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
NDV -X- _ I-Intervention
) -X- _ I-Intervention
are -X- _ O
currently -X- _ O
being -X- _ O
investigated -X- _ O
in -X- _ O
multiple -X- _ O
clinical -X- _ O
trials -X- _ O
for -X- _ O
oncolytic -X- _ O
cancer -X- _ O
therapy -X- _ O
in -X- _ O
the -X- _ O
United -X- _ O
States -X- _ O
and -X- _ O
abroad. -X- _ O
We -X- _ O
have -X- _ O
previously -X- _ O
reported -X- _ O
, -X- _ O
for -X- _ O
the -X- _ O
first -X- _ O
time -X- _ O
, -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
recombinant -X- _ O
NDVs -X- _ O
designed -X- _ O
for -X- _ O
enhanced -X- _ O
cancer -X- _ O
therapeutic -X- _ O
efficacy. -X- _ O
Specifically -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
shown -X- _ O
that -X- _ O
NDV -X- _ O
engineered -X- _ O
to -X- _ O
express -X- _ O
interleukin-2 -X- _ O
( -X- _ O
IL-2 -X- _ O
) -X- _ O
generates -X- _ O
a -X- _ O
robust -X- _ O
therapeutic -X- _ O
response -X- _ O
associated -X- _ O
with -X- _ O
increased -X- _ O
tumor-specific -X- _ O
T-cell -X- _ O
infiltration -X- _ O
after -X- _ O
intratumoral -X- _ O
administration -X- _ O
in -X- _ O
mice. -X- _ O
We -X- _ O
have -X- _ O
now -X- _ O
demonstrated -X- _ O
that -X- _ O
this -X- _ O
therapeutic -X- _ O
response -X- _ O
is -X- _ O
dependent -X- _ O
on -X- _ O
T -X- _ O
cells -X- _ O
and -X- _ O
we -X- _ O
have -X- _ O
investigated -X- _ O
the -X- _ O
potential -X- _ O
to -X- _ O
focus -X- _ O
the -X- _ O
NDV-induced -X- _ O
immune -X- _ O
response -X- _ O
toward -X- _ O
a -X- _ O
tumor-associated -X- _ O
antigen -X- _ O
( -X- _ O
TAA -X- _ O
) -X- _ O
to -X- _ O
enhance -X- _ O
the -X- _ O
inherent -X- _ O
therapeutic -X- _ O
efficacy -X- _ O
of -X- _ O
NDV -X- _ O
further. -X- _ O
We -X- _ O
found -X- _ O
that -X- _ O
intratumoral -X- _ O
treatments -X- _ O
of -X- _ O
tumor-bearing -X- _ B-Patient
mice -X- _ I-Patient
with -X- _ O
recombinant -X- _ B-Intervention
NDV -X- _ I-Intervention
expressing -X- _ I-Intervention
a -X- _ I-Intervention
model -X- _ I-Intervention
TAA -X- _ I-Intervention
elicited -X- _ O
an -X- _ O
enhanced -X- _ B-Outcome
tumor- -X- _ I-Outcome
specific -X- _ I-Outcome
response -X- _ I-Outcome
, -X- _ I-Outcome
resulting -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
significant -X- _ I-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
complete -X- _ I-Outcome
tumor -X- _ I-Outcome
regressions -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
control -X- _ I-Outcome
NDV. -X- _ I-Outcome
Additionally -X- _ O
, -X- _ O
coadministration -X- _ B-Outcome
of -X- _ I-Outcome
NDV -X- _ I-Outcome
expressing -X- _ I-Outcome
a -X- _ I-Outcome
model -X- _ I-Outcome
TAA -X- _ I-Outcome
with -X- _ I-Outcome
NDV -X- _ I-Outcome
expressing -X- _ I-Outcome
IL-2 -X- _ I-Outcome
enhanced -X- _ I-Outcome
the -X- _ I-Outcome
TAA-directed -X- _ I-Outcome
response -X- _ I-Outcome
and -X- _ I-Outcome
led -X- _ I-Outcome
to -X- _ I-Outcome
more -X- _ I-Outcome
complete -X- _ I-Outcome
tumor -X- _ I-Outcome
regressions. -X- _ I-Outcome
Our -X- _ O
results -X- _ O
show -X- _ O
that -X- _ O
TAA-directed -X- _ B-Outcome
immunotherapy -X- _ I-Outcome
by -X- _ I-Outcome
oncolytic -X- _ I-Outcome
recombinant -X- _ I-Outcome
NDV -X- _ I-Outcome
alone -X- _ I-Outcome
or -X- _ I-Outcome
in -X- _ I-Outcome
combination -X- _ I-Outcome
with -X- _ I-Outcome
IL-2 -X- _ I-Outcome
results -X- _ I-Outcome
in -X- _ I-Outcome
an -X- _ I-Outcome
enhanced -X- _ I-Outcome
therapeutic -X- _ I-Outcome
efficacy -X- _ I-Outcome
and -X- _ O
warrant -X- _ O
consideration -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
cancer -X- _ O
therapies -X- _ O
based -X- _ O
on -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
oncolytic -X- _ O
NDV -X- _ O
. -X- _ O

